8-K filing — Xeris Biopharma Holdings, Inc. (XERS)
Filed: 2026-10-14 AccNo: 0001867096-26-000091 Size: 170 KB Item 8.01: Other Events
Stocks · News reference
Xeris Biopharma Files Patent Infringement Lawsuits Related To Its KEYEVIS Product In U.S. District Court In New Jersey
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.
Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call
Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive